The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | COVID-19: treating CLL patients
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the management of chronic lymphocytic leukemia (CLL) patients during the COVID-19 pandemic. Specifically, Dr Tam debates the use of BTK inhibitors in patients positive for SARS‐CoV‐2. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
